Partnerships

Milagen has had many research and commercial partners over the years to advance our product line and introduce them to the market. Scroll down to learn more.

We are currently looking for like-minded investors and commercial partners to co-develop and commercialize our cancer tests. Please contact us below to start the discussion.

Select Partnerships

Milagen entered into partnerships with researchers from leading academic institutions and medical centers in order to advance the development of immunodiagnostic assays for early detection, prognosis and therapy management. These collaborations provided invaluable clinical expertise, unbiased feedback, and the chance for third-party validation of its products.

National Institutes of Health (NIH)

November 21, 2001

Agreement with the NCI for access to multi-year collection of cancer patients sera sponsored by the NIH.

University of Chicago, Pritzker School of Medicine

September 21, 2001

Milagen to initiate collaboration with University of Chicago, Pritzker School of Medicine.

Abnovel Corporation

September 16, 2001

Milagen, Inc. and Abnovel Corporation to generate monoclonal antibodies to selected disease targets for diagnostic applications.

University of California, San Francisco

November 30, 2000

Initiation of research collaboration with University of California San Francisco.

Institut Gustave Roussy

October 27, 2000

Initiation of collaboration with Institut Gustave Roussy, Paris, France.

Multiple Hospitals in Paris, France

July 8, 2000

Milagen to initiate research collaboration with Assistance Publique des Hopitaux de Paris, Hopital d'Enfants Armand-Trousseau, Polyclinique de Pneumologie Pediatrique, Asthma Center.

Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico

June 25, 1999

Agreement with Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, to access state-of-the-art animal facility for the production of polyclonal and monoclonal antibodies.